ByTrending Posts
Can Novartis AG’s $3 Billion AI-Driven Oncology Bet…
Key Highlights: AI-Led Drug Discovery Accelerates Target Identification and ValidationNovartis AG’s acquisition of SNV4818 from Synnovation Therapeutics, Inc.…
How Will Emerging Drug Pricing Policies Reshape the…
The global biopharmaceutical industry is entering a new policy-driven era as governments intensify efforts to control drug costs,…
Strategic Industry Release: How AI Companies Led Biopharma…
Artificial intelligence companies emerged as critical innovation partners for the global biopharmaceutical industry in 2025, reshaping how drugs…
AI in Life Sciences: A Multi-Billion Dollar Transformation…
Artificial intelligence is rapidly becoming one of the most transformative forces in the life sciences industry. Global investment…
Strategic Industry Analysis: What the Biggest Biopharma Deals…
The global biopharmaceutical industry experienced a powerful wave of strategic dealmaking in 2025 as major pharmaceutical companies accelerated…
EU Regulators Back CAMCEVI: A Key Step Toward…
Foresee Pharmaceuticals has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of…
Can aTyr Pharma’s Upcoming FDA Meeting Accelerate the…
aTyr Pharma has reported its fourth-quarter and full-year 2025 financial results while outlining a pivotal regulatory milestone ahead:…
Did the Zealand Pharma–Roche Obesity Partnership Hit an…
A closely watched obesity drug collaboration between Zealand Pharma and Roche has encountered an unexpected setback after early…
Indian Biopharma Faces Freight Surge Amid US-Iran Escalation
India’s biopharma sector confronts $300-500M export losses as US-Iran war disrupts Gulf shipping, spiking container surcharges to $3,500–$5,000…
Trending Posts
Latest Stories
Roche’s Gazyva Wins Second FDA Priority Review in Months — Is Obinutuzumab Becoming Nephrology’s Next Blockbuster?
Key Highlights A Landmark Regulatory Milestone for a Disease With No Approved Treatments Roche’s announcement…
Can Attovia Therapeutics’ Nasdaq IPO Signal a Broader Biotech Funding Revival Backed by Goldman Sachs and Deep Track Capital?
Key Highlights A Landmark Filing Reflecting Renewed Confidence in Biopharma Innovation Attovia Therapeutics’ decision to…
Can OpenLoop’s Acquisition of Hey Revia Redefine How AI Automates Telehealth Communication for Thousands of Providers?
Key Highlights A Landmark Acquisition Strengthening OpenLoop’s Virtual Care Ecosystem OpenLoop, the Iowa-based telehealth infrastructure…
Is the $2.5 Billion Insilico Medicine-Bora Pharmaceuticals Alliance the Blueprint for AI-Native Pharma’s Next Decade?
Key Highlights A Landmark Alliance Bridging AI Discovery and Global Manufacturing In a move set…
Gallery
